A carregar...
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. Homologous recombination deficiency...
Na minha lista:
| Publicado no: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433712/ https://ncbi.nlm.nih.gov/pubmed/30672100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14133 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|